MJA
MJA InSight
MJA Careers
Viewpoint

Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia’s Pharmaceutical Benefits Scheme?

Thomas A Faunce
Med J Aust 2007; 187 (4): 240-242.

Unless the federal government changes the course of our medicines policy with intention, Australia’s pricing of patented pharmaceuticals is likely to follow inequitable US trends

Thomas A Faunce, BA LLB, BMed, PhD, Senior Lecturer
Medical School and College of Law, Australian National University, Canberra, ACT.
Article References: 
Reference Text: 
Australian Government Department of Health and Ageing. National Medicines Policy. 2000. http://www.health.gov.au/internet/wcms/Publishing.nsf/Content/nmp-objectives-policy.htm/$FILE/nmp2000.pdf (accessed Apr 2007).
Reference Order: 
1
PubMed ID: 
Reference Text: 
Australian Government Department of Foreign Affairs and Trade. Australia–United States Free Trade Agreement. 2004. http://www.dfat.gov.au/trade/negotiations/us.html (accessed Mar 2007).
Reference Order: 
2
PubMed ID: 
Reference Text: 
Australian Government Department of Health and Ageing. PBAC outcomes and public summary documents. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-outcomes-and-public-summary-documents (accessed Jun 2007).
Reference Order: 
3
PubMed ID: 
Reference Text: 
Australian Government. Independent Review (PBS). http://www.independentreviewpbs.gov.au (accessed Jun 2007).
Reference Order: 
4
PubMed ID: 
Reference Text: 
US Department of Health and Human Services. Australia–US Medicines Working Group holds first meeting. 2006. http://www.globalhealth.gov/Australia_meds_011406.shtml (accessed Jan 2006; no longer available).
Reference Order: 
5
PubMed ID: 
Reference Text: 
Australian Government Department of Health and Ageing. PBS Latest News. PBS cost recovery consultations are happening. http://www.pbs.gov.au/html/healthpro/news/article?id=NEWS-2007-04-18-Cost_Recovery.xml (accessed Jun 2007).
Reference Order: 
6
PubMed ID: 
Reference Text: 
Ray WA, Stein CM. Reform of drug regulation — beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201.
Reference Order: 
7
PubMed ID: 
16407517
Reference Text: 
Lopert R (Medical Adviser, Pharmaceutical Benefits Branch, Department of Health and Ageing). Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Official Committee Hansard, Monday 21 June 2004: FTA 24. http://www.aph.gov.au/Senate/committee/freetrade_ctte/hearings/ (accessed Feb 2007).
Reference Order: 
8
PubMed ID: 
Reference Text: 
Harvey KJ, Faunce TA, Lokuge B, Drahos P. Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme? Med J Aust 2004; 181: 256-259.
Reference Order: 
9
PubMed ID: 
15347273
Reference Text: 
Faunce T, Doran E, Henry D, et al. Assessing the impact of the Australia–United States Free Trade Agreement on Australian and global medicines policy. Global Health 2005; 1: 15.
Reference Order: 
10
PubMed ID: 
16209703
Reference Text: 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (US) 21 USC conference agreement House Report 108-391 Title XI – Access to Pharmaceuticals. Bipartisan Trade Promotion Authority Act of 2002 (US), 107-210 §2102 (b) (8) (D).
Reference Order: 
11
PubMed ID: 
Reference Text: 
US Department of Commerce International Trade Administration. Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, research and development, and innovation. Washington, DC: ITA, 2004. http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf (accessed Apr 2006).
Reference Order: 
12
PubMed ID: 
Reference Text: 
Scherer P (Head Health Division). Delegates to the OECD Group on Health. Pharmaceutical pricing policy [letter]. Organisation for Economic Co-Operation and Development. 20 Sep 2005.
Reference Order: 
13
PubMed ID: 
Reference Text: 
Deady S (Special Negotiator, Office of Trade Negotiations, Department of Foreign Affairs and Trade). Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Official Committee Hansard, Monday 21 June 2004: FTA 12, FTA 16. http://www.aph.gov.au/Senate/committee/freetrade_ctte/hearings/ (accessed Feb 2007).
Reference Order: 
14
PubMed ID: 
Reference Text: 
Vaile M (Deputy Prime Minister and Minister for Trade). Joint press conference at the office of the United States Trade Representative, Washington, DC. 7 Mar 2006. http://www.trademinister.gov.au/transcripts/2006/060306_us_jt.html (accessed Jun 2007).
Reference Order: 
15
PubMed ID: 
Reference Text: 
Laming A. Let’s overhaul the Pharmaceutical Benefits Scheme. The Australian 2006; 10 Jan: 10.
Reference Order: 
16
PubMed ID: 
Reference Text: 
Australian Government Department of Health and Ageing. AUSFTA – Medicines Working Group – 2007 meeting statement. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-ausfta-statement-2007 (accessed Jun 2007).
Reference Order: 
17
PubMed ID: 
Reference Text: 
Office of the US Trade Representative. Proposed United States–Korea FTA texts. Chapter Five. Pharmaceuticals and medical devices. http://www.ustr.gov/Trade_Agreements/Bilateral/Republic_of_Korea_FTA/Draft_Text/Section_Index.html (accessed May 2007).
Reference Order: 
18
PubMed ID: 
Reference Text: 
Faunce TA, Lexchin J. Linkage pharmaceutical evergreening in Canada and Australia. Aust New Zealand Health Policy 2007; 4: 8. http://www.anzhealthpolicy.com/content/4/1/8 (accessed Jun 2007).
Reference Order: 
19
PubMed ID: 
17543113
Reference Text: 
Delaat W (Chairman of Medicines Australia). National Press Club speech 2005. Pharma in Focus 2005; 8 Aug. http://www.pharmainfocus.com.au/news.asp?newsid=825 (accessed Jun 2007).
Reference Order: 
20
PubMed ID: 
17543113

The full contents of this page are only available to subscribers.